Biocompatible prosthetic tissue

Abstract From the Canadian patent

Crosslinked tissue is contacted with one or more toxicity reducing solutions to remove cytotoxicity associated with the crosslinking process. In particular, crosslinked tissue can be contacted with an inorganic sulfuroxygen group to form chemical adducts of aldehydes and the inorganic sulfuroxygen group. Preferably, the cytotoxicity reduced crosslinked tissue has no residual cytotoxicity. In preferred embodiments a plurality of toxicity , reducing agents are used to detoxify the tissue. Preferred toxicity reducing agents include, for example, inorganic sulfur-oxygen ions such as bisulfate , and thiosulfate, organic sulfates amines, ammonia/ammonium, and surfactants.